AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Worldwide RNA Interference (RNAi) Drug Delivery Industry to 2025 - by Application, Technology and Region - ResearchAndMarkets.com

December 29, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 29, 2020--

The “RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

The global RNA interference (RNAi) drug delivery market grew at a CAGR of around 7% during 2014-2019. Looking forward, the publisher expects the global RNA interference (RNAi) drug delivery market to continue its moderate growth during the next five years.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens.

Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

ADVERTISEMENT

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • CureVac AG
  • Dicerna Pharmaceuticals Inc.
  • Gradalis Inc.
  • Ionis Pharmaceuticals Inc
  • Merck & Co. Inc.
  • Moderna Inc.
  • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
  • Silence Therapeutics Plc
  • Sirnaomics Inc

Key Questions Answered in This Report:

  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Application

6.1 Infectious Disease

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Cardiology

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 Oncology

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 Neurology

6.4.1 Market Trends

6.4.2 Market Forecast

6.5 Ophthalmology

6.5.1 Market Trends

6.5.2 Market Forecast

6.6 Urology

6.6.1 Market Trends

6.6.2 Market Forecast

6.7 Metabolic Disorders

6.7.1 Market Trends

6.7.2 Market Forecast

6.8 Others

6.8.1 Market Trends

6.8.2 Market Forecast

7 Market Breakup by Technology

7.1 Nanoparticle Drug Delivery

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Pulmonary Drug Delivery

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Nucleic Acid Drug Delivery

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Aptamer Drug Delivery

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Others

7.5.1 Market Trends

7.5.2 Market Forecast

8 Market Breakup by Region

8.1 North America

8.2 Asia Pacific

8.3 Europe

8.4 Latin America

8.5 Middle East and Africa

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure

13.2 Key Players

13.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/ykw2zb

View source version on businesswire.com:https://www.businesswire.com/news/home/20201229005186/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/29/2020 06:41 AM/DISC: 12/29/2020 06:41 AM

http://www.businesswire.com/news/home/20201229005186/en